Premium
Long‐Term Therapy of Antitachycardia Pacing for Supraventricular Tachycardia
Author(s) -
JUNG WERNER,
MLETZKO RALPH,
MANZ MATTHIAS,
ÜLUUDERITZ BERNDT
Publication year - 1992
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.1992.tb03062.x
Subject(s) - medicine , supraventricular tachycardia , supraventricular arrhythmia , tachycardia , cardiology , refractory (planetary science) , concomitant , anesthesia , atrial fibrillation , physics , astrobiology
Long‐term antitachycardia pacing therapy with the InterTach 262–12 and 262–16 was evaluated in 32 consecutive patients (mean age 50 ± 13 years) with recurrent, drug refractory Supraventricular tachycardia. AV nodal reentrant tachycardia was present in 20 patients, Wolff‐Parkinson‐Whife syndrome in ten patients, and a reentrant tachycardia due to Mahaim fibers in one patient. During follow‐up of 39 ± 17 months, 250 persistent tachycardia episodes occurred in 22 patients. By adjusting detection and termination mode, recurrent Supraventricular tachycardia could be controlled in 19 of 32 patients (60%) by antitachycardia pacing alone. Concomitant antiarrhythmic drug therapy was required in ten of 32 patients (30%). During follow‐up antitachycardia pacing became ineffective in three patients (10%). Thus, chronic antitachycardia pacing proved to be safe and effective in selected patients with drug refractory Supraventricular tachycardia and could significantly improve quality of life by rapid termination of recurrent supraventricular tachycardia episodes.